Advances in our understanding of cancer immunology and the mechanisms by which cancer immunotherapies exert their effects have translated into increasingly positive patient outcomes.
The recent successes of immunotherapeutics, particularly immune checkpoint inhibitors, have served to demonstrate the power and potential of immune-based treatment strategies. Now there is a need to build upon what we have learned in order to effectively treat more patients with cancer.
SITC Cancer Immunotherapy CONNECT is your hub for live and online educational opportunities. SITC CONNECT also provides access to all of the latest data in the field of tumor immunology and cancer immunotherapy. Connect to other researchers in the Cancer Immunotherapy CONNECT Open Forum and submit your manuscript to the Journal for ImmunoTherapy of Cancer (JITC) to drive progress in the field.
Submission Period Closes: Tuesday, February 20, 2018 at 5 p.m. EST
*Must be a SITC member to apply.
The majority of NSCLC patients do not still respond to PD-1/PD-L1 treatment. Chemotherapy is theorized to increase the release of tumor antigen resulting in increased response with immunotherapy. ...
more details in our latest news story: bit.ly/2CpnCWQ ------------------------------ Jade Parker Editor Future Science Group ------------------------------
Course Name: 6 th Annual Lung Cancer Symposium
Course Date: Friday, March 2, 2018
Course Co-Directors and Planners : Ralph Zinner, MD; Gregory Kane, MD; Judith Alberto, RPh; Rita ...
This message was posted by a user wishing to remain anonymous Hi All His is an attempt to find answers on the observed onset of effect on Opdivo / Nivolumab treatment. If you are a doctor ...
View More Researcher Resources
In this video, hear SITC Annual Meeting delegates explain the purpose and benefits for joining thousands of their colleagues at the Annual Meeting & Pre-Conference Programs, share how far the science of cancer immunotherapy has progressed and predict where the field is headed. Also, learn about the benefits of becoming a member of SITC.
For more than 30 years the Society for Immunotherapy of Cancer (SITC) has been fighting for treatment and a cure for cancer through research and collaboration. SITC members all over the world are leading the charge against cancer. We’re traveling the globe to meet these thought leaders and demonstrate the crucial work that they’re doing to impact advances in both the science and clinical application of immunotherapy.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com